Neurocrine Biosciences (NBIX) Projected to Post Earnings on Wednesday

Neurocrine Biosciences (NASDAQ:NBIX) is projected to announce its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of $2.36 per share and revenue of $804.21 million for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 4:30 PM ET.

Neurocrine Biosciences Stock Up 1.0%

Shares of Neurocrine Biosciences stock opened at $138.98 on Wednesday. The firm has a market cap of $13.86 billion, a PE ratio of 33.25, a price-to-earnings-growth ratio of 0.64 and a beta of 0.31. Neurocrine Biosciences has a 52 week low of $84.23 and a 52 week high of $160.18. The business’s fifty day simple moving average is $142.97 and its 200-day simple moving average is $140.38.

Insider Buying and Selling

In other Neurocrine Biosciences news, CEO Kyle Gano sold 36,400 shares of the stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $132.70, for a total value of $4,830,280.00. Following the sale, the chief executive officer owned 140,407 shares of the company’s stock, valued at $18,632,008.90. This trade represents a 20.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Leslie V. Norwalk sold 1,190 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $155.09, for a total value of $184,557.10. Following the completion of the transaction, the director owned 6,239 shares of the company’s stock, valued at $967,606.51. The trade was a 16.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,966 shares of company stock valued at $8,625,166 in the last three months. 4.30% of the stock is currently owned by insiders.

Institutional Trading of Neurocrine Biosciences

Large investors have recently made changes to their positions in the company. Sivia Capital Partners LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth about $215,000. Employees Retirement System of Texas acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter worth about $149,000. Geneos Wealth Management Inc. raised its position in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares in the last quarter. Coldstream Capital Management Inc. lifted its stake in Neurocrine Biosciences by 8.3% during the third quarter. Coldstream Capital Management Inc. now owns 4,090 shares of the company’s stock worth $574,000 after purchasing an additional 315 shares during the last quarter. Finally, Virtus Advisers LLC boosted its holdings in Neurocrine Biosciences by 297.5% in the third quarter. Virtus Advisers LLC now owns 2,584 shares of the company’s stock valued at $363,000 after purchasing an additional 1,934 shares in the last quarter. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on NBIX shares. Canaccord Genuity Group increased their target price on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Stifel Nicolaus upped their price objective on shares of Neurocrine Biosciences from $183.00 to $188.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Morgan Stanley reaffirmed an “equal weight” rating and set a $175.00 price objective (up previously from $173.00) on shares of Neurocrine Biosciences in a research report on Thursday, January 8th. Royal Bank Of Canada boosted their target price on Neurocrine Biosciences from $160.00 to $180.00 and gave the company an “outperform” rating in a research report on Monday, December 8th. Finally, UBS Group lowered their price target on Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $174.25.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.